Urothelial Bladder Cancer — Microlearning Activity 2 with Dr Terence Friedlander: ESMO Congress 2025 Review
Oncology Today with Dr Neil Love
00:00
Dicidumab-vidotin (DV) plus PD-1 first-line data
Terence reviews the positive Chinese phase 3 DV+teriplimab trial showing strong PFS, OS, and durability versus cis/gem.
Play episode from 05:17
Transcript
